Friday, September 17
01:25 AM

36 new medicines approved, prices of several reduced

1 May 2021

The Ministry of Health’s (MoH) committee responsible for registration of pharmaceutical companies and pricing of medicines has approved the registration of 36 new medicines and reduced the prices of several others. 

The committee, chaired by Dr Mohammed Hamdan al Rubaie, director general of Pharmaceutical Affairs and Drug Control, held its third meeting of 2021 to discuss applications and pricing of a number of new drugs, the re-pricing of a number of other registered medicines, as well reviewing the availability of some medicines in the Omani market.

The committee approved applications for the registration of 36 new medicines following the fulfilment of all the conditions and procedures stipulated in implementing the pharmacy practice and pharmaceutical laws. 

Conditions outlined the scientific evaluation of the contents and uses of these drugs, as well as the evaluation of bio-equivalence studies for some of them, in addition to conducting chemical, physical and biological analyses to ensure that they conform to the standard specifications.

Furthermore, the committee approved the prices of three drugs provided by companies because of the market needs and the lack of alternatives. It further adopted lower prices than those presented by the manufacturers of about 29 medicines after reviewing and comparing the prices provided to Oman with those of the GCC countries. The committee postponed the registration of four drugs to request new price certificates from companies.

The committee reviewed the prices of six innovative drugs from a number of international companies, and decided to reduce the prices of these drugs, in addition to reducing the prices of 13 generic drugs in line with the reduction of innovative drugs.

Moreover, the committee agreed to re-register 86 medicines and review their prices as the re-registration and reduction of the prices of 20 medicines, and the re-registration of the rest of the drugs were approved while maintaining the previously recorded prices.

© 2021 Apex Press and Publishing. All Rights Reserved.